Long-term update of a phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma

Julie Marie Vose, B. K. Link, M. L. Grossbard, M. Czuczman, A. Grillo-Lopez, R. I. Fisher

Research output: Contribution to journalArticle

41 Citations (Scopus)

Abstract

The present study aimed to determine the long-term safety and efficacy of chimeric anti-CD 20 antibody rituxan (rituximab, Biogen IDEC, San Diego, CA, USA; Genentech, South San Francisco, CA, USA) in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) chemotherapy in previously untreated patients with aggressive non-Hodgkin's lymphoma (NHL). Thirty-three patients with previously untreated aggressive B-cell NHL received six infusions of rituximab (375 mg/m2 per dose) on day 1 of each cycle of CHOP chemotherapy, given on day 3 of each cycle of therapy. Currently, the patients now have a median follow-up of 63 months (range 34-82 months). The overall response (OR) rate was 94% and the complete response (CR) rate was 61% at the end of therapy. Of the 33 patients, 2 patients experienced disease progression and subsequently died of their disease, 2 patients experienced disease progression but were alive at last follow-up following additional therapy, and 2 patients died without experiencing disease progression: one due to a cerebral vascular accident at 9 months after therapy and a second patient due to small cell lung carcinoma at 55 months. The 5-year survival rate was 88% (95% confidence interval (CI) 72-97) and the 5-year progression-free survival was 82% (95% CI 64-93). There were no long-term adverse events noted directly related to the rituximab. The long-term follow-up of patients in this phase II trial of rituximab with CHOP chemotherapy for previously untreated aggressive NHL demonstrates a high response rate, which remains very durable with high 5-year overall and progression-free survivals.

Original languageEnglish (US)
Pages (from-to)1569-1573
Number of pages5
JournalLeukemia and Lymphoma
Volume46
Issue number11
DOIs
StatePublished - Nov 1 2005

Fingerprint

Non-Hodgkin's Lymphoma
Drug Therapy
Disease Progression
Disease-Free Survival
Confidence Intervals
Rituximab
San Francisco
Small Cell Lung Carcinoma
Vincristine
B-Cell Lymphoma
Therapeutics
Prednisone
Doxorubicin
Cyclophosphamide
Accidents
Blood Vessels
Survival Rate
Safety
Antibodies

Keywords

  • Chemotherapy
  • Diffuse large B-cell lymphoma
  • Non-Hodgkin's lymphoma

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Long-term update of a phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. / Vose, Julie Marie; Link, B. K.; Grossbard, M. L.; Czuczman, M.; Grillo-Lopez, A.; Fisher, R. I.

In: Leukemia and Lymphoma, Vol. 46, No. 11, 01.11.2005, p. 1569-1573.

Research output: Contribution to journalArticle

Vose, Julie Marie ; Link, B. K. ; Grossbard, M. L. ; Czuczman, M. ; Grillo-Lopez, A. ; Fisher, R. I. / Long-term update of a phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma. In: Leukemia and Lymphoma. 2005 ; Vol. 46, No. 11. pp. 1569-1573.
@article{5402018e71a946d0a6a9eeaba56623ba,
title = "Long-term update of a phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma",
abstract = "The present study aimed to determine the long-term safety and efficacy of chimeric anti-CD 20 antibody rituxan (rituximab, Biogen IDEC, San Diego, CA, USA; Genentech, South San Francisco, CA, USA) in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) chemotherapy in previously untreated patients with aggressive non-Hodgkin's lymphoma (NHL). Thirty-three patients with previously untreated aggressive B-cell NHL received six infusions of rituximab (375 mg/m2 per dose) on day 1 of each cycle of CHOP chemotherapy, given on day 3 of each cycle of therapy. Currently, the patients now have a median follow-up of 63 months (range 34-82 months). The overall response (OR) rate was 94{\%} and the complete response (CR) rate was 61{\%} at the end of therapy. Of the 33 patients, 2 patients experienced disease progression and subsequently died of their disease, 2 patients experienced disease progression but were alive at last follow-up following additional therapy, and 2 patients died without experiencing disease progression: one due to a cerebral vascular accident at 9 months after therapy and a second patient due to small cell lung carcinoma at 55 months. The 5-year survival rate was 88{\%} (95{\%} confidence interval (CI) 72-97) and the 5-year progression-free survival was 82{\%} (95{\%} CI 64-93). There were no long-term adverse events noted directly related to the rituximab. The long-term follow-up of patients in this phase II trial of rituximab with CHOP chemotherapy for previously untreated aggressive NHL demonstrates a high response rate, which remains very durable with high 5-year overall and progression-free survivals.",
keywords = "Chemotherapy, Diffuse large B-cell lymphoma, Non-Hodgkin's lymphoma",
author = "Vose, {Julie Marie} and Link, {B. K.} and Grossbard, {M. L.} and M. Czuczman and A. Grillo-Lopez and Fisher, {R. I.}",
year = "2005",
month = "11",
day = "1",
doi = "10.1080/10428190500217312",
language = "English (US)",
volume = "46",
pages = "1569--1573",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "11",

}

TY - JOUR

T1 - Long-term update of a phase II study of rituximab in combination with CHOP chemotherapy in patients with previously untreated, aggressive non-Hodgkin's lymphoma

AU - Vose, Julie Marie

AU - Link, B. K.

AU - Grossbard, M. L.

AU - Czuczman, M.

AU - Grillo-Lopez, A.

AU - Fisher, R. I.

PY - 2005/11/1

Y1 - 2005/11/1

N2 - The present study aimed to determine the long-term safety and efficacy of chimeric anti-CD 20 antibody rituxan (rituximab, Biogen IDEC, San Diego, CA, USA; Genentech, South San Francisco, CA, USA) in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) chemotherapy in previously untreated patients with aggressive non-Hodgkin's lymphoma (NHL). Thirty-three patients with previously untreated aggressive B-cell NHL received six infusions of rituximab (375 mg/m2 per dose) on day 1 of each cycle of CHOP chemotherapy, given on day 3 of each cycle of therapy. Currently, the patients now have a median follow-up of 63 months (range 34-82 months). The overall response (OR) rate was 94% and the complete response (CR) rate was 61% at the end of therapy. Of the 33 patients, 2 patients experienced disease progression and subsequently died of their disease, 2 patients experienced disease progression but were alive at last follow-up following additional therapy, and 2 patients died without experiencing disease progression: one due to a cerebral vascular accident at 9 months after therapy and a second patient due to small cell lung carcinoma at 55 months. The 5-year survival rate was 88% (95% confidence interval (CI) 72-97) and the 5-year progression-free survival was 82% (95% CI 64-93). There were no long-term adverse events noted directly related to the rituximab. The long-term follow-up of patients in this phase II trial of rituximab with CHOP chemotherapy for previously untreated aggressive NHL demonstrates a high response rate, which remains very durable with high 5-year overall and progression-free survivals.

AB - The present study aimed to determine the long-term safety and efficacy of chimeric anti-CD 20 antibody rituxan (rituximab, Biogen IDEC, San Diego, CA, USA; Genentech, South San Francisco, CA, USA) in combination with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) chemotherapy in previously untreated patients with aggressive non-Hodgkin's lymphoma (NHL). Thirty-three patients with previously untreated aggressive B-cell NHL received six infusions of rituximab (375 mg/m2 per dose) on day 1 of each cycle of CHOP chemotherapy, given on day 3 of each cycle of therapy. Currently, the patients now have a median follow-up of 63 months (range 34-82 months). The overall response (OR) rate was 94% and the complete response (CR) rate was 61% at the end of therapy. Of the 33 patients, 2 patients experienced disease progression and subsequently died of their disease, 2 patients experienced disease progression but were alive at last follow-up following additional therapy, and 2 patients died without experiencing disease progression: one due to a cerebral vascular accident at 9 months after therapy and a second patient due to small cell lung carcinoma at 55 months. The 5-year survival rate was 88% (95% confidence interval (CI) 72-97) and the 5-year progression-free survival was 82% (95% CI 64-93). There were no long-term adverse events noted directly related to the rituximab. The long-term follow-up of patients in this phase II trial of rituximab with CHOP chemotherapy for previously untreated aggressive NHL demonstrates a high response rate, which remains very durable with high 5-year overall and progression-free survivals.

KW - Chemotherapy

KW - Diffuse large B-cell lymphoma

KW - Non-Hodgkin's lymphoma

UR - http://www.scopus.com/inward/record.url?scp=28244439191&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=28244439191&partnerID=8YFLogxK

U2 - 10.1080/10428190500217312

DO - 10.1080/10428190500217312

M3 - Article

C2 - 16236611

AN - SCOPUS:28244439191

VL - 46

SP - 1569

EP - 1573

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 11

ER -